These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32096498)

  • 1. Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy.
    Li C; Qiu Q; Liu M; Liu X; Hu L; Luo X; Lai C; Zhao D; Zhang H; Gao X; Deng Y; Song Y
    Biomater Sci; 2020 Apr; 8(8):2189-2201. PubMed ID: 32096498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity.
    Luo X; Liu M; Hu L; Qiu Q; Liu X; Li C; Lu M; Liu Y; Zhang T; Zhou S; McClements DJ; Jia X; Deng Y; Song Y
    Int J Pharm; 2018 Aug; 547(1-2):315-329. PubMed ID: 29886095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic Acid Conjugate-Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size.
    Wang S; Yang S; Lai X; Song Y; Hu L; Li C; Shi T; Liu X; Deng Y; Chen G
    AAPS PharmSciTech; 2021 Jan; 22(1):16. PubMed ID: 33389218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment.
    Hu L; Luo X; Zhou S; Zhu J; Xiao M; Li C; Zheng H; Qiu Q; Lai C; Liu X; Deng Y; Song Y
    Pharm Res; 2019 May; 36(7):97. PubMed ID: 31076925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.
    Luo X; Hu L; Zheng H; Liu M; Liu X; Li C; Qiu Q; Zhao Z; Cheng X; Lai C; Su Y; Deng Y; Song Y
    Drug Deliv; 2018 Nov; 25(1):1200-1212. PubMed ID: 29791241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy.
    Zheng H; Li J; Wang M; Luo X; Qiu Q; Hu L; Li C; Song Y; Deng Y
    Int J Pharm; 2019 Mar; 558():187-200. PubMed ID: 30654062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialic acid-modified doxorubicin liposomes target tumor-related immune cells to relieve multiple inhibitions of CD8
    Du Z; Sui D; Xin D; Tang X; Li M; Liu X; Deng Y; Song Y
    J Liposome Res; 2024 Sep; 34(3):464-474. PubMed ID: 38196168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Dose on Neutrophil-Mediated Delivery of Nanoparticles for Tumor-Targeting Therapy Strategies.
    Liu M; Li C; NaYan ; Zhao D; Zhang H; Li J; Tang X; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2021 Mar; 22(3):89. PubMed ID: 33665749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy.
    Li C; Lai C; Qiu Q; Luo X; Hu L; Zheng H; Lu Y; Liu M; Zhang H; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2019 May; 20(5):188. PubMed ID: 31093777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.